Amphotericin B is Still the Drug of Choice for Invasive Aspergillosis

作者
Brahm H. Segal,Thomas J. Walsh
出处
期刊:American Journal of Respiratory and Critical Care Medicine [American Thoracic Society]
卷期号:174 (1): 102a-103 被引量:7
标识
DOI:10.1164/ajrccm.174.1.102a
摘要

We read with interest the recent article by Drs. Segal andWalsh, wherein the authors review the epidemiology, diagnosis, and management of invasive aspergillosis (1). The authors recommend voriconazole as the drug of choice in the treatment of invasive aspergillosis. However, we do not agree with the recommendations of the authors that voriconazole be considered the new standard of care for invasive aspergillosis. We believe that it is too early to accept voriconazole as the drug of choice for invasive aspergillosis. Amphotericin B is a highly effective antifungal agent, and is used as the gold standard against which newer agents are compared in trials of antifungal drugs. The conclusion that amphotericin B is inferior to voriconazole is based on two published trials (2, 3); however, both the trials are limited by their study design (4). The first trial was flawed by its design in using the deoxycholate preparation without requirements for premedication (used for minimizing infusion-related toxicity), or substitutionwith fluid and electrolytes (to reduce nephrotoxicity) (2). Moreover, voriconazole was given on an average of 77 d, but amphotericin B was given only for 10 d, precluding any meaningful comparison of the two study drugs. The second trial was a noninferiority trial that compared voriconazole with liposomal amphotericin B as an empirical treatment of fever of unknown origin in neutropenic cancer patients (3). Despite misleading definitions, voriconazole was significantly inferior to amphotericin B (4, 5). In fact, there was less survival in the voriconazole group, and a claimed significant reduction in the so-called breakthrough fungal infections (defined as those confirmed more than 24 h postenrollment) in favor of voriconazole disappeared when baseline infections that persisted despite treatment (infections arbitrarily excluded from analysis) were included (4). Thus, the available evidence does not support a recommendation to use voriconazole instead of amphotericin B for the treatment of invasive aspergillosis. To the contrary, amphotericin B is significantly more effective than voriconazole and is currently the drug of choice (6).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酒辞发布了新的文献求助10
刚刚
邓不利多i完成签到,获得积分10
1秒前
zzz发布了新的文献求助10
1秒前
陈y完成签到,获得积分10
1秒前
ny66完成签到,获得积分10
2秒前
2秒前
ish168178发布了新的文献求助10
2秒前
寻123完成签到,获得积分10
3秒前
3秒前
3秒前
3秒前
3秒前
珍珠发布了新的文献求助30
3秒前
柒九发布了新的文献求助10
3秒前
3秒前
领导范儿的应助被绯红逍遥采纳,获得10
4秒前
4秒前
kris发布了新的文献求助10
4秒前
QDU的应助被嘟嘟嘟采纳,获得20
4秒前
支摇伽发布了新的文献求助10
4秒前
复嘟嘟完成签到,获得积分10
5秒前
Nole的应助被观的采纳,获得30
5秒前
DW的应助被瑞达采纳,获得10
5秒前
搜集达人的应助被张顺采纳,获得10
5秒前
义气的哈密瓜完成签到,获得积分10
6秒前
搜集达人的应助被Hello_Alina采纳,获得10
6秒前
小黄发布了新的文献求助10
6秒前
Celeste完成签到 ,获得积分10
6秒前
kipo完成签到 ,获得积分10
6秒前
王十七发布了新的文献求助10
6秒前
7秒前
wanci的应助被爽朗的小王同学采纳,获得10
7秒前
瓶子完成签到 ,获得积分10
7秒前
甜美无剑发布了新的文献求助10
7秒前
李健的小迷弟的应助被youyyuy采纳,获得10
8秒前
9秒前
彳亍完成签到,获得积分10
9秒前
10秒前
斯文败类的应助被王新涛采纳,获得10
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180713
求助须知:如何正确求助?哪些是违规求助? 9570752
关于积分的说明 21814119
捐赠科研通 7776960
什么是DOI,文献DOI怎么找? 3433298
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479287